ICHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ICHR is not a strong buy right now for a beginner long-term investor, even though the pre-market move and analyst upgrades are constructive. The stock has supportive moving averages and positive analyst sentiment, but the MACD is weakening, earnings are imminent, recent financials still show declining revenue and negative income, and the options market is unusually active with elevated implied volatility. For an impatient investor with $50,000-$100,000 to deploy, the better call is to hold off on buying today and wait for confirmation after earnings or a cleaner entry.
ICHR is trading pre-market at 67.07, up 1.67%, with the current price near the pivot of 67.221. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports the broader trend. However, the MACD histogram is -0.237 and negatively expanding, showing near-term momentum is weakening. RSI_6 at 53.71 is neutral, so the stock is neither oversold nor overbought. Key levels to watch are support at 63.121 and resistance at 71.32, with higher resistance at 73.852. Overall, the trend is constructive but not decisively strong enough for an immediate long-term entry without further confirmation.
Analysts have been steadily raising price targets and maintaining Buy ratings. B. Riley lifted its target to $82 and said AI compute is driving demand in semiconductor capital equipment. Stifel, TD Cowen, DA Davidson, Needham, and Oppenheimer have all been constructive, citing a strengthening cycle, improving gross margin trajectory, and a return to growth. The upcoming earnings release on 2026-05-04 could act as a catalyst if the company confirms the recovery trend.
No news in the recent week means there is no fresh positive event catalyst today. The latest quarter showed revenue down 4.15% year over year and gross margin down to 10.06%, while net income remained negative at -15.96M. The MACD is deteriorating, and the stock has a stated downside tendency in similar pattern analysis over the next week and month. Heavy put volume and elevated implied volatility also signal caution around the earnings event.
In Q4 2025, Ichor posted revenue of 223.6M, down 4.15% year over year, so top-line growth is still not fully back. Net income improved year over year but remained negative at -15.96M, and EPS was -0.46. Gross margin fell to 10.06%, down 3.55 points year over year, showing profitability is still under pressure despite signs of recovery. The latest quarter season was Q4 2025.
Analyst sentiment has improved sharply over the last few months. Multiple firms raised targets and reiterated Buy/Outperform ratings, with B. Riley moving from $52 to $75 and then to $82, Stifel raising to $66, DA Davidson to $53, TD Cowen to $55, and Needham to $48. The Wall Street pros view is bullish on cycle recovery, AI-driven wafer fab equipment demand, and margin upside. The main con is that the recent financials have not yet fully confirmed durable profitability, so the bullish target revisions are ahead of the numbers rather than fully matched by them.
